Treatment duration of trastuzumab in early HER2-positive breast cancer

Record ID 32018005508
Project Status: Ongoing
Anticipated Publish Date: 2024
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Switzerland
MeSH Terms
  • Breast Neoplasms
  • Trastuzumab
  • Duration of Therapy
  • Chemotherapy, Adjuvant
  • Receptor, ErbB-2
  • PROMs
  • efficacy
  • effectiveness
  • safety
  • costs
  • economics
  • cost-effectiveness
  • budget impact
  • legal
  • social
  • ethical
  • organisational
  • trastuzumab
  • pertuzumab
  • HER2-positive
  • breast cancer
  • duration of treatment
  • reduced treatment duration
  • HER2-positive early breast cancer
Organisation Name: Swiss Federal Office of Public Health (FOPH)
Contact Address: Federal Office of Public Health, Schwarzenburgstrasse 157, CH-3003 Berne, Switzerland
Contact Name: Stephanie Vollenweider
Contact Email:
Copyright: Swiss Federal Office of Public Health
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.